Alterations in Gut Microbiota and Serum Metabolites in Children with Mycoplasma pneumoniae Pneumonia
Shu Wang,Chengzhong Liu,Ruipei Ding,Shumei Wang,Yousheng Ye,Maozhang He
DOI: https://doi.org/10.2147/idr.s490547
2024-11-27
Infection and Drug Resistance
Abstract:Shu Wang, 1, &ast Chengzhong Liu, 2, &ast Ruipei Ding, 2 Shumei Wang, 2 Yousheng Ye, 1 Maozhang He 2 1 Department of Geriatrics, The First People's Hospital of Hefei, Hefei, 230061, People's Republic of China; 2 Department of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, People's Republic of China &astThese authors contributed equally to this work Correspondence: Maozhang He; Yousheng Ye, Email ; Background: Over the past years, there has been a significant increase in the incidence of Mycoplasma pneumoniae (MP) infections, particularly among pediatric patients, nationwide. An emerging body of research has established a link between dysbiosis of the host microbiome and the metabolic functioning of the host, which contributes to the development of respiratory diseases. Methods: A total of 25 children were included in the study, comprising 15 pneumonia patients and 10 healthy children. Stool samples were collected from all participants to analyze the 16S ribosomal RNA (16S rRNA) gene, while serum samples were prepared for untargeted metabolomics to qualitatively and quantitatively assess short-chain fatty acids. Results: The gut microbial composition of individuals with Mycoplasma pneumoniae pneumonia (MPP) exhibited significant differences compared to healthy children. Notably, diseased children demonstrated higher microbial diversity and an enrichment of opportunistic pathogens, such as Erysipelatoclostridium and Eggerthella . Analysis revealed elevated levels of two specific short-chain fatty acids, namely acetic acid and isobutyric acid, in the MPP group, suggesting their potential as biomarkers for predicting MP infection. Metabolomic signature analysis identified a significant increase in major classes of glycerophospholipids in the MPP group. Moreover, we identified a total of 750 significant correlations between gut microbiota and circulating serum metabolites. MPP enriched genera Erysipelatoclostridium and Eggerthella , exhibited negative associations with indole-3-butyric acid. Additionally, Eggerthella showed a positive correlation with inflammatory metabolites LPC (18:0). Discussion: Collectively, these findings provide novel insights into the selection of potential biomarkers and the pathogenesis of MPP in children based on the gut microbiota and systemic circulating metabolites. Keywords: Mycoplasma pneumoniae , gut microbiota, serum metabolomics, short-chain fatty acids, inflammation Mycoplasma pneumoniae (MP) is one of the primary pathogens responsible for both upper and lower respiratory tract infections in humans. It can transmit between individuals through respiratory droplets containing microorganisms, which are dispersed via coughing or sneezing. The incubation period for MP can vary from one to three weeks, and infections are prevalent in both children and adults globally. 1,2 The proportion of MP in pneumonia cases increases progressively with age. It has become the most common pathogen in community-acquired pneumonia among children, accounting for 10% to 40% of community-acquired pneumonia (CAP) cases. 3–5 In adults in Europe, the incidence of endemic pneumonia ranges from 4% to 8%, which can escalate to 20–70% during epidemics. 6 The prevalence of MP exhibits seasonality, indicating that while MP infections occur throughout the year in Beijing, there is a peak during the pneumonia season from October to January, where MP accounts for 27.78% of CAP cases, reflecting a pattern of annual epidemic peaks. 7 Macrolide antibiotics, as the first-line treatment for MP infections, have seen a rise in the prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) due to their extensive use. 8 There is a significant variation in the prevalence of MRMP across different countries and regions globally. In Western Europe and North America, the prevalence of MRMP is below 30%, 9 whereas it is considerably higher in Asian countries, with rates in our country reaching up to 90%. 10 MP promotes the occurrence of inflammatory responses by inducing proliferation of B lymphocytes and T lymphocytes, secretion of major histocompatibility complex proteins, and release of various cytokines such as interleukins, interferons, tumor necrosis factor, and colony-stimulating factors. This leads to increased airway obstruction and heightened airway hyperresponsiveness, exacerbating asthma. 11 Apart from directly causing damage to the lungs, MP can mimic host cell components, activate the host's immune r -Abstract Truncated-
pharmacology & pharmacy,infectious diseases